← All trials
NCT05117476
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 29, 2021
- Primary completion
- Sep 30, 2025
- Completion date
- Mar 31, 2026
- First posted
- Nov 11, 2021
- Last posted
- Nov 11, 2021
- Enrollment
- 148
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cullinan Oncology, LLCLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.